NCT00716794View on ClinicalTrials.gov

A Phase I/II Study of HE3235 in Patients With Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Prostate Cancer
Interventions
DRUG

HE3235

HE3235 will be administered orally in 28 day cycles.

Trial Locations (8)

10065

New York

28204

Charlotte

78229

San Antonio

85260

Scottsdale

92024

Encinitas

94115

San Francisco

95661

Roseville

98109

Seattle

Sponsors
All Listed Sponsors
lead

Harbor Therapeutics

INDUSTRY